Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harrow, Inc. filings document an ophthalmic pharmaceutical business built around branded products and ImprimisRx, including operating results, stockholder communications and Regulation FD presentations tied to its U.S. commercialization strategy. Current reports disclose material events such as product and business updates, executive appointments and compensation arrangements, the completed Melt Pharmaceuticals acquisition, and capital-structure matters involving senior unsecured notes due 2030.
Proxy materials cover shareholder voting matters, board governance and executive compensation. The filing record also includes disclosures on material agreements, risk-related cautionary statements, and clinical or regulatory topics connected to Harrow's ophthalmic product portfolio.
Key Takeaway: Harrow Inc.’s 2025 Annual Meeting (18-Jun-2025) produced broad shareholder support on every agenda item, reaffirming governance stability without introducing immediate balance-sheet or earnings effects.
A strong quorum of 31.27 million shares (85.2 % of the 36.69 million entitled) was present. All four director nominees—Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail and Perry J. Sternberg—were re-elected with at least 98.8 % of votes cast, signalling investor confidence in existing leadership.
The new 2025 Incentive Stock and Awards Plan passed with 21.70 million ‘For’ (90.5 % of votes cast, excl. broker non-votes) versus 1.77 million ‘Against’. The plan gives the board fresh equity-compensation capacity, potentially increasing future dilution if fully utilised.
Audit matters were routine: shareholders ratified Crowe LLP for FY-2025 with 31.23 million ‘For’ (99.8 %), removing audit-continuity uncertainty. Advisory votes showed 94.1 % support for executive pay and 82.5 % support for holding a say-on-pay vote every year.
No M&A, financing, or earnings guidance was disclosed. Overall, this 8-K reflects standard corporate-governance maintenance rather than a catalyst for near-term valuation change.